There are 2137 resources available
1315P - Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Presenter: Enriqueta Felip
Session: E-Poster Display
Resources:
Abstract
1316P - Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-9LA
Presenter: David Stenehjem
Session: E-Poster Display
Resources:
Abstract
1317P - Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Presenter: Remei Blanco
Session: E-Poster Display
Resources:
Abstract
1318P - Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Presenter: Chiara Dellepiane
Session: E-Poster Display
Resources:
Abstract
1319P - Interdependence of KRAS and TP53 mutations in predicting benefit from immune checkpoint inhibitor (ICI) in non-squamous NSCLC
Presenter: Xiaoyan Li
Session: E-Poster Display
Resources:
Abstract
1320P - Impact of body mass index (BMI) in non-small cell lung cancer patients treated with anti PD-1 immunotherapy (IO): A retrospective cohort study
Presenter: Ana Catarina Bravo
Session: E-Poster Display
Resources:
Abstract
1321P - Advanced lung cancer inflammation index (ALI score) as a biomarker of immunotherapy efficacy in patients with advanced non-small cell lung cancer: A nationwide analysis in Greece
Presenter: Giannis Mountzios
Session: E-Poster Display
Resources:
Abstract
1322P - Real-world treatment patterns and immunotherapy (IO) sequencing based on PD-L1 TPS in European patients with metastatic NSCLC
Presenter: Erin Janowicz
Session: E-Poster Display
Resources:
Abstract
1323P - Natural killer cell activity as a prognostic biomarker in non-small cell lung cancer patients treated with check-point inhibitors
Presenter: Sara Wen
Session: E-Poster Display
Resources:
Abstract
1324P - Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
Presenter: Elizabeth Dudnik
Session: E-Poster Display
Resources:
Abstract